| Popis: |
Gates B Colbert,1 Hector M Madariaga,2 Anna Gaddy,3 Mohamed E Elrggal,4 Edgar V Lerma5 1Texas A&M University College of Medicine at Dallas, Dallas, TX, USA; 2Department of Internal Medicine, Lahey Hospital & Medical Center, Burlington, MA, USA; 3Department of Internal Medicine, Medical College of Wisconsin, Milwaukee, WI, USA; 4Division of Nephrology, Kidney and Urology Center, Alexandria, Egypt; 5Section of Nephrology, University of Illinois at Chicago, Chicago, IL, USACorrespondence: Gates B Colbert, Department of Internal Medicine, Baylor University Medical Center at Dallas, 3417 Gaston Ave, Suite 875, Dallas, TX, 75246, USA, Tel +1-972-388-5970, Email Gates.Colbert@BSWHealth.orgAbstract: Chronic kidney disease guidelines and disease modifying therapy have seen a dramatic shift in the last 5 years. The SGLT2 inhibitor class of medications has been catapulted from hyperglycemia management medications, to cardiovascular and kidney disease improvement therapies. Multiple trials looking at dedicated cardiovascular and kidney endpoints have resulted in favorable results. This review will target empagliflozin and the exciting journey that it has taken along this path. Empagliflozin has been studied for hyperglycemia, cardiovascular, and kidney hard outcome endpoints. Both patients with diabetes and without have been rigorously studied and shown surprising results. The major implications for patients on empagliflozin will be shown. Future studies and directions are highly anticipated to add to the growing knowledge of the SGLT2 inhibitor class, as well as discover possibilities for new disease states to benefit from empagliflozin.Keywords: empagliflozin, SGLT2, chronic kidney disease, cardiovascular disease, diabetes, end stage kidney disease |
